The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Genzyme; Heron; Regeneron; Squibb
Speakers' Bureau - Genzyme; Regeneron; Squibb
Research Funding - Novartis (Inst); Regeneron (Inst)
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Guardant Health AMEA; Kyowa Kirin International; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Guardant Health AMEA; Janssen; Kyorin; Lilly; Merck; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Wu-Chou Su
Consulting or Advisory Role - Bayer Schering Pharma; Lilly; Merck; MSD Oncology
 
Benjamin Philip Levy
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Loxo (Inst); Merck (Inst); Turning Point Therapeutics (Inst)
 
Olivier Rixe
Employment - Daiichi Sankyo Pharmaceutical
Stock and Other Ownership Interests - Bexion; Daiichi Sankyo Pharmaceutical
Research Funding - Daiichi Sankyo Pharmaceutical; Kyowa Kirin; Nanobiotix; Oxford BioTherapeutics; Quantum Santa Fe
 
Tsung-Ying Yang
No Relationships to Disclose
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sunshine Guojian (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Panos Savvides
No Relationships to Disclose
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Manuel Domine
Consulting or Advisory Role - AstraZeneca; MSD; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; MSD; Takeda
 
Konstantinos Leventakos
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)
Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)
 
Mariano Provencio
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly O.; Merck; Pfizer; Roche; Takeda
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Pierre Fabre; Roche; Takeda
Patents, Royalties, Other Intellectual Property - P201731067. Prognosis methods for patients with folicularlymphoma. España. 16/05/2017. FIBHUPH; PCT/ES2018/070463. M
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly O.; Pierre Fabre; Roche; Takeda
 
Atsushi Horiike
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; EP-SOGO; Kyowa Hakko Kirin; Lilly Japan; Merck; Novartis; Taiho Oncology
Research Funding - BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Nihonkayaku (Inst)
 
Edward Pan
No Relationships to Disclose
 
Daisy Lin
Employment - Northwell Health (I)
 
Jessie Gu
Employment - Daiichi Sankyo Pharmaceutical
Stock and Other Ownership Interests - Daiichi Sankyo Pharmaceutical
 
Priyanka Basak
No Relationships to Disclose
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)